KDventures AB Completes Patient Follow-Up in PBC Trial; Data Due Early Nov 2026
KDventures said its portfolio company Umecrine Cognition has reached last patient out in a randomized Phase 1b/2a study of golexanolone in PBC. Data readout is expected in early November 2026 after database lock and independent analysis.Material DetailsContext by AI AnalystThis is an operational mi…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.